Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company develops proteolysis targeting chimeras (PROTAC) targeted prot...
Q2 2026
Aug 5, 2026
Q1 2026
May 11, 2026
FY 2025
Feb 24, 2026
Q4 2025
Q3 2025
Nov 5, 2025
